Keywords
How to Cite
Abstract
Purpose. Study the relationship between risk factors such as obesity and impaired glucose tolerance in people of different ages. Materials and methods. Were examined 299 people of different ages. According to the BMI they were divided into groups of people without obesity: 20-39 years old — 43 people, 40-59 years — 52 people and 102 people at the age of 60 years and with obesity — at the age of 40-59 years — 35 and 67 people in aged 60 and over. A standard glucose-tolerant test was conducted for all subjects. In addition to the definition of BMI, waist and hip sizes, insulin resistance index (HOMA-IR) and were determined lipid blood spectrum too. Results. In this work it is shown that with the age the frequency of development of pre-diabetic disorders increases. The incidence of pre-diabetic changes increases with age: an increase of impaired fasting glucose (IFG) 11.6% of people aged 20-39, 23% in people aged 40-59 and increases at the age of 60 and older than 22.0% in humans without obesity; a combined disorder of glucose tolerance is absent in the age group of 20-39 years, it is noted in 5.6% at the age of 40-59 and reaches 15.0% in people 60 years of age and older. In people with obesity, a combined impairment of middle-aged glucose tolerance occurs in 17.7% of the subjects, and at the age of 60 and older it increases to 41.33%. HOMA-IR (р<0.05) has a higher level of glucose tolerance in comparison with both young and middle-aged people and people over the age of 60 years and older without impairment of glucose tolerance. In the elderly group with NTG, a higher level of glucose, HOMA-IR, total cholesterol levels, triglycerides, LDL cholesterol and low LDL cholesterol. Conclusion. These changes suggest that there is an atherogenic dyslipidemia, which is associated with insulin resistance, obesity and impaired glucose tolerance in older people (found in people of middle age and more pronounced in people over the age of 60), which may be considered as one of the leading causes of cardiometabolic risk.
References
2. Aldossari KK, Aldiab A, Al-Zahrani JM, Al-Ghamdi SH, Abdelrazik M, Batais MA, Javad S, et al. Prevalence of prediabetes, diabetes, and its associated risk factors among males in Saudi Arabia: a population-based survey. J Diabetes Res. 2018; Article ID2194604,12 p.
3. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2011;34(Suppl 1):62-9.
4. Gossain VV, Aldasouqi S. The challenge of undiagnosed prediabetes, diabetes and associated cardiovascular disease. Intern J Diabetes Mellitus. 2010;2(1):43-6.
5. World Health Organization. Waist circumference and waist-hip ratio report of a WHO expert consultation Geneva, 8-11 December 2008.
6. American Diabetes Association. Classification and diagnosis of diabetes. Diabetes Care. 2016;39(Suppl 1):13-22.
7. King H, Aubert RE, Herman WH. Global burden of diabetes 1995-2025. Prevalence, numerical estimates, and projections. Diabetes Care. 1998;21:1414-31.
8. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases:executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). EurHeart J. 2007;28(1):88-136.
9. Vogeser M, König D, Frey I, Predel HG, Parhofer KG, Berg A. Fasting serum insulin and the homeostasis model of insulin resistance (HOMA-IR) in the monitoring of lifestyle interventions in obese person. Clin Biochem. 2007;40(13-14):964-8.
10. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation. 2002 Decemb;106(25).
11. Климов АН. Причины и условия развития атеросклероза. Превентивная кардиология. Под ред. ГИ Косицкого. Москва: Медицина, 1977; 260-321. (Klimov AN. Causes and conditions for the development of atherosclerosis. Klimov AN. Causes and conditions for the development of atherosclerosis. Preventivnaya kardiologiya. Pod red. GI Kositskogo. Moskva: Meditsina, 1977; 260-321).
12. Климов АН, Никульчева НГ. Обмен липидов и липопротеидов и его нарушения. СПб: Питер Ком, 1999;512 с. (Klimov AN, Nikul’cheva NG. Metabolism of lipids and lipoproteins and its disorders. St. Petersburg: Piter Kom, 1999;512 p.)
13. Friedewald WT, Kevy IR, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
14. Baez-Duarte BG, Sánchez-Guillén M del C, Pérez-Fuentes R, Zamora-Ginez I, Leon-Chavez BA, Revilla-Monsalve C, Islas-Andrade S. β-cell function is associated with metabolic syndrome in Mexican subjects. Diabetes Metab Syndr Obes. 2010;3:301-9.
15. Iribarren C, Reed DM, Burchfiel CM, Dwyer JH. Serum total cholesterol and mortality. Confounding factors and risk, modification in Japanese-American men. JAMA. 1995 Jun;273(24):1926-32.
16. Kolovou GD, Anagnostopoulou КК, Cokkinos DV. Pathophysiology of dyslipidaemia in the metabolic syndrome. Postgrad Med J. 2005;81:358-66.
This work is licensed under a Creative Commons Attribution 4.0 International License.